Van't Veer LJ - Search Results

1

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ. Bueno-de-Mesquita JM, et al. Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. Breast Cancer Res Treat. 2009. PMID: 18819002

2

A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.

van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 1997 Aug 15;57(16):3478-85. Cancer Res. 1997. PMID: 9270016

3

ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.

Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ. Broeks A, et al. Hum Mutat. 1998;12(5):330-7. doi: 10.1002/(SICI)1098-1004(1998)12:5<330::AID-HUMU6>3.0.CO;2-H. Hum Mutat. 1998. PMID: 9792409

4

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.

Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. Ligtenberg MJ, et al. Br J Cancer. 1999 Mar;79(9-10):1475-8. doi: 10.1038/sj.bjc.6690235. Br J Cancer. 1999. PMID: 10188893 Free PMC article.

5

Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells.

Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van' t Veer LJ, Rodenhuis S. Lambrechts AC, et al. Breast Cancer Res Treat. 1999 Aug;56(3):219-31. doi: 10.1023/a:1006261731125. Breast Cancer Res Treat. 1999. PMID: 10573113

6

Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas.

van Dijk MA, Hart AA, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 2000 Feb 1;60(3):530-3. Cancer Res. 2000. PMID: 10676630

7

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. Broeks A, et al. Am J Hum Genet. 2000 Feb;66(2):494-500. doi: 10.1086/302746. Am J Hum Genet. 2000. PMID: 10677309 Free PMC article.

8

Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations.

Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van T Veer LJ. Broeks A, et al. Int J Radiat Biol. 2000 May;76(5):693-8. doi: 10.1080/095530000138367. Int J Radiat Biol. 2000. PMID: 10866292

9

Gene expression profiling predicts clinical outcome of breast cancer.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. van 't Veer LJ, et al. Nature. 2002 Jan 31;415(6871):530-6. doi: 10.1038/415530a. Nature. 2002. PMID: 11823860

10

Detection of circulating breast tumor cells by differential expression of marker genes.

Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ. Bosma AJ, et al. Clin Cancer Res. 2002 Jun;8(6):1871-7. Clin Cancer Res. 2002. PMID: 12060630

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

391 results

Search Page